EA201290712A1 - Альфа-излучающие комплексы - Google Patents

Альфа-излучающие комплексы

Info

Publication number
EA201290712A1
EA201290712A1 EA201290712A EA201290712A EA201290712A1 EA 201290712 A1 EA201290712 A1 EA 201290712A1 EA 201290712 A EA201290712 A EA 201290712A EA 201290712 A EA201290712 A EA 201290712A EA 201290712 A1 EA201290712 A1 EA 201290712A1
Authority
EA
Eurasian Patent Office
Prior art keywords
complexes
alpha
radiating
tissue
provides
Prior art date
Application number
EA201290712A
Other languages
English (en)
Other versions
EA026305B1 (ru
Inventor
Томас Рамдаль
Original Assignee
Алгета Ас
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алгета Ас filed Critical Алгета Ас
Publication of EA201290712A1 publication Critical patent/EA201290712A1/ru
Publication of EA026305B1 publication Critical patent/EA026305B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

В настоящем изобретении предложен комплекс, обеспечивающий направленную доставку к ткани, содержащий обеспечивающую направленную доставку к ткани группировку, октадентатный гидроксипиридинон-содержащий лиганд и ион альфа-излучающего радионуклида тория. Кроме того, в изобретении предложены терапевтические способы применения таких комплексов, способы их получения и применения, а также наборы и фармацевтические композиции, содержащие такие комплексы.
EA201290712A 2010-02-12 2011-02-14 Альфа-излучающие комплексы EA026305B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1002508.8A GB201002508D0 (en) 2010-02-12 2010-02-12 Product
PCT/EP2011/052158 WO2011098611A2 (en) 2010-02-12 2011-02-14 Alpha-emitting complexes

Publications (2)

Publication Number Publication Date
EA201290712A1 true EA201290712A1 (ru) 2014-12-30
EA026305B1 EA026305B1 (ru) 2017-03-31

Family

ID=42110714

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290712A EA026305B1 (ru) 2010-02-12 2011-02-14 Альфа-излучающие комплексы

Country Status (26)

Country Link
US (2) US9724436B2 (ru)
EP (2) EP3417883B1 (ru)
JP (2) JP5878483B2 (ru)
KR (1) KR101931382B1 (ru)
CN (1) CN103608043B (ru)
AU (1) AU2011214281B2 (ru)
BR (1) BR112012020304B1 (ru)
CA (1) CA2789433C (ru)
CY (1) CY1120362T1 (ru)
DK (2) DK2533817T3 (ru)
EA (1) EA026305B1 (ru)
ES (2) ES2674875T3 (ru)
GB (1) GB201002508D0 (ru)
HR (2) HRP20180996T1 (ru)
HU (2) HUE049465T2 (ru)
IL (2) IL221416A (ru)
LT (2) LT3417883T (ru)
MX (1) MX343405B (ru)
NZ (1) NZ601867A (ru)
PL (2) PL3417883T3 (ru)
PT (2) PT2533817T (ru)
RS (2) RS60314B1 (ru)
SG (1) SG183279A1 (ru)
SI (2) SI3417883T1 (ru)
TR (1) TR201809149T4 (ru)
WO (1) WO2011098611A2 (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008797A2 (en) 2006-07-10 2008-01-17 The Regents Of The University Of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
EP2816038B8 (en) 2009-08-24 2019-12-25 Lumiphore, Inc. Hopo chelators
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes
WO2014110372A1 (en) * 2013-01-14 2014-07-17 Molecular Insight Pharmaceuticals Triazine based radiopharmaceuticals and radioimaging agents
US11453652B2 (en) 2013-03-15 2022-09-27 Lumiphore, Inc. Di-macrocycles
GB201310028D0 (en) 2013-06-05 2013-07-17 Algeta Asa Pharmaceutical preparation
MA41176A (fr) * 2014-12-17 2017-10-24 Bayer As Complexes radio-pharmaceutiques
CA2972080A1 (en) * 2014-12-22 2016-06-30 Lumiphore, Inc. Functionalized linear ligands and complexes thereof
GB201504064D0 (en) 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600153D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600161D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope purification method
PE20190168A1 (es) * 2016-03-24 2019-02-01 Bayer Pharma AG Complejos radiofarmaceuticos
CU20180149A7 (es) 2016-06-10 2019-07-04 Bayer As Complejos radio-farmacéuticos
CA3054248A1 (en) 2017-02-24 2018-08-30 Bayer As Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor
UA127532C2 (uk) 2017-12-13 2023-09-27 Сайєнконс Ас Комплекс, який містить сполуку, що націлюється на psma, зв'язану з радіонуклідом свинцю або торію
CA3110754A1 (en) 2018-08-28 2020-03-05 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
WO2020081174A1 (en) * 2018-10-16 2020-04-23 Nant Holdings Ip, Llc Alpha emitter compositions and methods
US20220125960A1 (en) 2019-02-21 2022-04-28 Bayer Aktiengesellschaft Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates
EP3927339A1 (en) 2019-02-22 2021-12-29 Bayer Aktiengesellschaft Combination of ar antagonists and targeted thorium conjugates
AR119479A1 (es) 2019-07-25 2021-12-22 Bayer As Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer
EP4281477A2 (en) 2021-01-22 2023-11-29 Bayer Aktiengesellschaft Lrrc15 antibodies and conjugates thereof
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68925904T2 (de) 1988-05-25 1996-10-31 The United States Of America, Represented By The Secretary, U.S. Department Of Commerce, Springfield, Va. Makrocyclische chelate und verwendungsverfahren
CA2034484C (en) 1989-06-19 2000-08-15 Maurits W. Geerlings Radioimmunotherapy using .alpha.-particles emission
WO1993020852A2 (en) 1992-04-13 1993-10-28 The Dow Chemical Company Macrocyclic chelating agents, chelates and conjugates thereof
US5624901A (en) 1994-04-15 1997-04-29 The Regents Of The University Of California 3-hydroxy-2(1H)-pyridinone chelating agents
ATE266006T1 (de) * 1995-06-14 2004-05-15 Univ California 3-hydroxy-2(1h)-pyridone als chelatbildner
WO1998016254A1 (en) 1996-10-17 1998-04-23 Immunomedics, Inc. Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
AU5729898A (en) 1996-12-18 1998-07-15 Emory University Polycationic oligomers
NO310544B1 (no) 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
NO314537B1 (no) 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
AU4906901A (en) 2000-02-25 2001-09-17 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
US7893223B2 (en) * 2001-07-17 2011-02-22 Bracco Imaging S.P.A. Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy
GB0213261D0 (en) 2002-06-10 2002-07-17 Anticancer Therapeutic Inv Sa Method
US20030228256A1 (en) 2002-06-11 2003-12-11 Inverardi Luca A. Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations
US20030086868A1 (en) 2002-08-12 2003-05-08 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
ITMI20022411A1 (it) 2002-11-14 2004-05-15 Bracco Imaging Spa Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate.
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
US20060228297A1 (en) 2003-04-15 2006-10-12 Roy Larsen Thorium-227 for use in radiotherapy of soft tissue disease
KR101274867B1 (ko) * 2003-04-15 2013-06-13 알게타 에이에스 연조직 질환의 방사선 치료에 사용하기 위한 토륨-227
PL1735013T3 (pl) 2004-02-20 2012-07-31 Algeta Asa Cząstki hydroksyapatytu alfa- i beta-emitujące
EP1763372B1 (en) * 2004-06-25 2016-11-30 The European Union, represented by the European Commission Radionuclides for medical use
GB0423565D0 (en) 2004-10-22 2004-11-24 Algeta As Formulation
WO2008008797A2 (en) * 2006-07-10 2008-01-17 The Regents Of The University Of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
EP2051968B1 (en) 2006-08-15 2020-04-29 The Regents of the University of California Luminescent macrocyclic lanthanide complexes
US8158804B2 (en) * 2007-01-11 2012-04-17 Ge Healthcare As Chelating agents
US20110189088A1 (en) * 2009-12-24 2011-08-04 Lumiphore, Inc. Radiopharmaceutical complexes
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201007354D0 (en) 2010-04-30 2010-06-16 Algeta Asa Method
GB201007353D0 (en) 2010-04-30 2010-06-16 Algeta Asa Method
GB201105298D0 (en) 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes

Also Published As

Publication number Publication date
PL2533817T3 (pl) 2018-08-31
HRP20180996T1 (hr) 2018-08-10
TR201809149T4 (tr) 2018-07-23
HUE049465T2 (hu) 2020-09-28
EP2533817B1 (en) 2018-03-28
SI3417883T1 (sl) 2020-07-31
EP2533817A2 (en) 2012-12-19
GB201002508D0 (en) 2010-03-31
WO2011098611A3 (en) 2015-07-02
PT2533817T (pt) 2018-06-29
RS57360B1 (sr) 2018-08-31
AU2011214281A1 (en) 2012-08-30
PT3417883T (pt) 2020-06-01
WO2011098611A2 (en) 2011-08-18
HUE038013T2 (hu) 2018-09-28
PL3417883T3 (pl) 2020-08-24
US10682430B2 (en) 2020-06-16
NZ601867A (en) 2014-11-28
CN103608043A (zh) 2014-02-26
ES2674875T3 (es) 2018-07-04
AU2011214281B2 (en) 2014-01-16
JP5878483B2 (ja) 2016-03-08
CN103608043B (zh) 2017-07-28
US20170319721A1 (en) 2017-11-09
US20130183235A1 (en) 2013-07-18
US9724436B2 (en) 2017-08-08
LT2533817T (lt) 2018-07-10
CY1120362T1 (el) 2019-07-10
KR20120130769A (ko) 2012-12-03
EP3417883B1 (en) 2020-03-25
IL243303A (en) 2017-09-28
MX343405B (es) 2016-11-03
CA2789433C (en) 2019-01-15
IL243303A0 (en) 2016-04-21
DK3417883T3 (da) 2020-06-08
JP6125599B2 (ja) 2017-05-10
DK2533817T3 (en) 2018-07-16
SI2533817T1 (en) 2018-08-31
BR112012020304B1 (pt) 2019-12-10
HRP20200826T1 (hr) 2020-08-07
EA026305B1 (ru) 2017-03-31
IL221416A (en) 2016-03-31
SG183279A1 (en) 2012-09-27
KR101931382B1 (ko) 2018-12-20
IL221416A0 (en) 2012-10-31
JP2016029114A (ja) 2016-03-03
JP2013519658A (ja) 2013-05-30
EP3417883A1 (en) 2018-12-26
CA2789433A1 (en) 2011-08-18
RS60314B1 (sr) 2020-07-31
LT3417883T (lt) 2020-07-10
BR112012020304A2 (pt) 2016-04-26
ES2794853T3 (es) 2020-11-19
MX2012009260A (es) 2013-02-07

Similar Documents

Publication Publication Date Title
EA201290712A1 (ru) Альфа-излучающие комплексы
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
EA201890915A1 (ru) Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
UA109464C2 (ru) Спироксиндольные антагонисты mdm2
MX2021008977A (es) Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.
MX360391B (es) Composiciones liposomales combinadas para terapia contra el cancer.
MX2015000813A (es) Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
EA201691059A1 (ru) Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
MX346375B (es) Antagonistas de espiro-oxindol de mdm2.
EA201390993A1 (ru) Антитела к cd38
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
GB201209613D0 (en) New compounds
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
NZ710746A (en) Pyrrolobenzodiazepines and conjugates thereof
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
JO3438B1 (ar) مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
WO2015009726A3 (en) Medical uses of cd38 agonists
EA201400237A1 (ru) Фолатные конъюгаты альбуминсвязывающих частиц
WO2012024530A3 (en) Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
TR201903026T4 (tr) S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari.
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.